Initial treatment strategy for patients by disease stage
| Treatment . | Stage I . | Stage II . | Stage III/IV . | Total . |
|---|---|---|---|---|
| Radiation alone | 19 | |||
| 31 Gy | 2 | |||
| 36 Gy | 5 | 3 | ||
| 40 Gy | 6 | 2 | ||
| Dose unknown | 1 | |||
| Total | 14 | 5 | 0 | |
| Combined modality | 12 | |||
| R-CHOP + IFRT (24 Gy, n = 1; 30.6 Gy, n = 5; 36 Gy, n = 1) | 2 | 4 | 1 | |
| R + IFRT (30 Gy, n=1; 40 Gy, n=1) | 1 | 1 | 0 | |
| ABVD + STNI (40 Gy) | 0 | 1 | 0 | |
| COPP + IFRT (40 Gy) | 0 | 1 | 0 | |
| NOVP + IFRT (35 Gy) | 0 | 0 | 1 | |
| Total | 3 | 7 | 2 | |
| Chemotherapy alone | 27 | |||
| R-CHOP | 2 | 3 | 15 | |
| R-ABVD | 0 | 1 | 2 | |
| ABVD | 0 | 0 | 2 | |
| R | 0 | 1 | 1 | |
| Total | 2 | 5 | 20 | |
| Observation | 1 | 0 | 0 | 1 |
| Total | 20 | 17 | 22 | 59 |
| Treatment . | Stage I . | Stage II . | Stage III/IV . | Total . |
|---|---|---|---|---|
| Radiation alone | 19 | |||
| 31 Gy | 2 | |||
| 36 Gy | 5 | 3 | ||
| 40 Gy | 6 | 2 | ||
| Dose unknown | 1 | |||
| Total | 14 | 5 | 0 | |
| Combined modality | 12 | |||
| R-CHOP + IFRT (24 Gy, n = 1; 30.6 Gy, n = 5; 36 Gy, n = 1) | 2 | 4 | 1 | |
| R + IFRT (30 Gy, n=1; 40 Gy, n=1) | 1 | 1 | 0 | |
| ABVD + STNI (40 Gy) | 0 | 1 | 0 | |
| COPP + IFRT (40 Gy) | 0 | 1 | 0 | |
| NOVP + IFRT (35 Gy) | 0 | 0 | 1 | |
| Total | 3 | 7 | 2 | |
| Chemotherapy alone | 27 | |||
| R-CHOP | 2 | 3 | 15 | |
| R-ABVD | 0 | 1 | 2 | |
| ABVD | 0 | 0 | 2 | |
| R | 0 | 1 | 1 | |
| Total | 2 | 5 | 20 | |
| Observation | 1 | 0 | 0 | 1 |
| Total | 20 | 17 | 22 | 59 |
COPP, cyclophosphamide, doxorubicin, procarbazine, prednisone; R, rituximab; STNI, subtotal nodal irradiation.